All Stories

  1. News From the Severe Asthma Consensus 2025 Review
  2. Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the Newton study
  3. ALAT-SEPAR Consensus on the Definition and Classification of Asthma Exacerbations by Severity: A Move Toward International Standardization
  4. FEV1 decline and clinical predictors in asthma after 10 Years of follow-up: BMI as a modifiable risk factor
  5. Documento de consenso de asma grave. Actualización 2025
  6. Identification of Fractional Exhaled Nitric Oxide Cutoff Values for the Diagnosis of Asthma
  7. Reply to Letter: The Importance of Multidisciplinary Teams in the Evaluation of the Remission of Chronic Rhinosinusitis in Severe Asthma
  8. Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
  9. Spanish Consensus on Remission in Asthma (REMAS)
  10. The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review
  11. Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population
  12. Understanding Severe Asthma Through Small and Big Data in Spanish Hospitals: The PAGE Study
  13. Necesidades no cubiertas en asma alérgica grave
  14. Quality indicators in the rational management of severe asthma: A Spanish multidisciplinary consensus
  15. Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis
  16. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain
  17. Estudio de prevalencia de asma en población general en España
  18. What's New in the 2022 Consensus for Severe Asthma in Adults
  19. Evaluation of the Diagnostic Accuracy of Non-Specific Bronchial Provocation Tests in the Diagnosis of Asthma: A Randomized Cross-Over Study
  20. Documento de consenso de asma grave en adultos. Actualización 2022
  21. Documento de consenso de expertos para el control del asma en personas mayores
  22. Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
  23. El asma en las personas mayores también existe
  24. Referral Criteria for Asthma and the Pandemic: New Challenges, New Responses
  25. Criterios de derivación en asma: Actualización documento de consenso
  26. Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map
  27. Documento de consenso sobre asma y tabaquismo del Foro Autonómico de Asma de la SEPAR
  28. Asthma control and adherence to clinical practice guidelines: mission impossible?
  29. Preference for Easyhaler® Over Previous Dry Powder Inhalers in Asthma Patients: Results of the DPI PREFER Observational Study
  30. Documento de consenso de enfermería en asma 2020
  31. <p>A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future</p>
  32. La termoplastia en el punto de mira
  33. Documento de consenso de asma grave en adultos. Actualización 2020
  34. Control del asma y seguimiento de las guías de práctica clínica: ¿misión imposible?
  35. El manejo del asma como enfermedad inflamatoria crónica y problema sanitario global: documento de posicionamiento de las sociedades científicas
  36. Functional Endoscopic Sinus Surgery for Nasal Polyposis in Asthma Patients: Impact on Bronchial Inflammation
  37. PAGE Study: Summary of a study protocol to estimate the prevalence of severe asthma in Spain using big-data methods
  38. Referral Criteria for Asthma: Consensus Document
  39. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
  40. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
  41. Rinitis, poliposis nasal y su relación con el asma
  42. Dilemmas and New Paradigms in Asthma Management
  43. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
  44. Anxiety, Depression, and Asthma Control: Changes After Standardized Treatment
  45. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate–severe asthma
  46. Consensus on the Asthma–COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA)
  47. Predictive factors for moderate or severe exacerbations in asthma patients receiving outpatient care
  48. Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines
  49. Is the bronchodilator test an useful tool to measure asthma control?
  50. Quality Indicators of Asthma Care Derived From the Spanish Guidelines for Asthma Management (GEMA 4.0): A Multidisciplinary Team Report
  51. Predictors of 10-year smoking abstinence in smokers abstinent for 1 year after treatment
  52. Comparative study of bronchial provocation tests using methacholine or mannitol in bronchial asthma
  53. de Torres JP
  54. Guidelines for the Study of Nonspecific Bronchial Hyperresponsiveness in Asthma
  55. Normativa sobre el estudio de la hiperrespuesta bronquial inespecífica en el asma
  56. Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry
  57. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches
  58. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire
  59. Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía-2010
  60. Factors Predicting the Initiation of a Tobacco Cessation Program in Spain
  61. Neumonías adquiridas en la comunidad
  62. Protocolo de tratamiento empírico de las neumonías adquiridas en la comunidad
  63. Protocolo de tratamiento empírico de las neumonías nosocomiales
  64. Indicaciones e interpretación clínica del cultivo de esputo. Lavado bronquial
  65. Indicaciones e interpretación clínica de la prueba de la tuberculina. Quimioprofilaxis
  66. Tuberculosis pulmonar
  67. Premenstrual Asthma and Symptoms Related to Premenstrual Syndrome
  68. Premenstrual asthma and atopy markers
  69. Relación del test de control del asma (ACT) con la función pulmonar, niveles de óxido nítrico exhalado y grados de control según la Iniciativa Global para el Asma (GINA)
  70. Relationship of the Asthma Control Test (ACT) with Lung Function, Levels of Exhaled Nitric Oxide and Control According to the Global Initiative for Asthma (GINA)
  71. Variability in the prevalence of premenstrual asthma
  72. Documento de Consenso sobre la espirometría en Andalucía
  73. Documento de Consenso en Andalucía: enfermedad pulmonar obstructiva crónica
  74. Impact of Chronic Obstructive Pulmonary Disease on Activities of Daily Living: Results of the Multicenter EIME Study
  75. Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME
  76. Atención y prestación de servicios en materia de tabaquismo
  77. Exacerbations, Hospital Admissions and Impaired Health Status in Chronic Obstructive Pulmonary Disease
  78. Segundo documento de consenso sobre uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica
  79. Respuesta de los autores
  80. Una opinión contraria al incremento del número de cirujanos torácicos
  81. F.J. Álvarez Gutiérrez
  82. Distribución de neumólogos y cirujanos torácicos en España
  83. Neumonías adquiridas en la comunidad en pacientes mayores de 60 años. Incidencia de gérmenes atípicos y evolución clinicorradiológica
  84. Estudio prospectivo de 221 neumonías adquiridas en la comunidad seguidas de forma ambulatoria. Etiología y evolución clinicorradiológica
  85. Cartas al Editor
  86. Investigation of Tuberculosis Contacts in a Nonhospital Pneumology Practice
  87. Mediadores de la inflamación (proteína catiónica del eosinófilo, ECP) en población normal y pacientes con asma bronquial o rinitis alérgica